Sustained effects of grass pollen AIT

Abstract

To cite this article: Durham SR, on behalf of the GT‐08 investigators. Sustained effects of grass pollen AIT. Allergy 2011; 66 (Suppl. 95): 50–52.AbstractWe report the sustained efficacy of the SQ‐standardized grass allergy immunotherapy tablet Grazax® (Phleum pratense 75 000 SQ‐T/2,800 BAU, ALK, Denmark) from a 5‐year randomized, double‐blind, placebo‐controlled phase III trial. Adults with moderate‐to‐severe grass pollen allergy inadequately controlled by symptomatic medications were followed for 2 years after the completion of 3 years of treatment. The active group demonstrated a 31% reduction in median rhinoconjunctivitis symptom score over the season compared with placebo. Individual symptom scores favoured active treatment. Combined symptom and medication scores demonstrated a 33% reduction in medians with active treatment. Persistent clinical efficacy was accompanied by prolonged increases in allergen‐specific IgG4 antibodies and IgE‐blocking factor, confirming clinical and immunological tolerance for at least 2 years after the treatment completion. No safety issues were identified during follow‐up.